

| | | | | | | | | | | | |
|---|--|--|--|--|--|--|--|--|--|-----------------------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT | | | | | | | | | | ATTY. DOCKET NO. D-0021.5 | SERIAL NO. 09/967,237 |
| | | | | | | | | | | APPLICANT Zavada et al. | |
| | | | | | | | | | | FILING DATE September 27, 2001 | GROUP |

**U.S. PATENT DOCUMENTS**

| EXAM. INITIAL | DOCUMENT NUMBER | | | | | | | | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
|------------------|-----------------|---|---|---|---|---|---|----------|---------------|------|-------|---------------|----------------|
| DB | 5 | 3 | 8 | 7 | 6 | 7 | 6 | 02/07/95 | Zavada et al. | 536 | 23.5 | | |
| DB | 5 | 5 | 8 | 5 | 4 | 7 | 9 | 12/17/96 | Hoke et al. | 536 | 24.5 | | |
| | | | | | | | | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAM. INITIAL | DOCUMENT NUMBER | | | | | | | | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|------------------|-----------------|---|---|---|---|---|---|----------|------|---------|---|---------------|-----------------------|
| DB | 9 | 5 | 3 | 4 | 6 | 5 | 0 | 12/21/95 | WO | | C12N 15/12 C07K 14/02, C12N 1/21, 15/62, C12Q 1/68, A61K 39/00, C12N 5/16, C07K 16/10, C12N 15/07, G01N 33/50, A61K 48/00 | | |
| DB | 9 | 3 | 1 | 8 | 1 | 5 | 2 | 09/16/93 | WO | | C12N 15/33, 1/20, 5/10 A61K 39/12, C12N 15/62 C12P 21/08, A16K39/395 G01N 33/569 | | |
| DB | 8 | 8 | 0 | 8 | 8 | 5 | 4 | 11/17/88 | WO | | C07K 15/00, A61K 49/02 G01N 33/574, A61K 39/395 C12P 21/00//C12N 15/00 C12N 5/00 (C12P 21/00 C12R 1.91) | | |

OTHER DISCLOSURES

| | |
|----|---|
| DB | Anton et al., "Localized renal-cell carcinoma: detection of abnormal cells in peritumoral tissue. A cytophotometry and immunocytochemistry study," <u>World J. Urol.</u> , 13(3): 149-152 (1995). |
| DB | Bander et al., "Renal cancer imaging with monoclonal antibody G250," <u>J. Urol.</u> , 155 (5 Suppl.): 583A (Abstract 1088) (1996) |

EXAMINER


DATE CONSIDERED

3/10/04

ATTY. DOCKET NO.
D-0021.5SERIAL NO.
09/967,237APPLICANT
Zavada et al.FILING DATE
September 27, 2001

GROUP

INFORMATION DISCLOSURE STATEMENT



OTHER DISCLOSURES

| | |
|----|--|
| DS | Costa et al., "A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN," <u>Gynecologic Oncology</u> , 63: 337-344 (1996) |
| | Costa et al., "MN Protein Immunolocalization in Uterine Cervix Carcinoma With Glandular Differentiation - A Clinicopathologic Study of a New Cancer-specific Biomarker," <u>International Journal of Surgical Pathology</u> , 3(2): 73-82 (1995) |
| | Costa, M., "MN and Ki67 (MIB-1) in Uterine Cervix Carcinoma: Novel Biomarkers With Divergent Utility," <u>Human Pathology</u> , 27(3): 217-219 (March 1996) |
| | Cote, "Protein Antigen Helps Identify Early Cervical Abnormalities," <u>Women's Health Weekly</u> : News Section, p. 7 (March 30, 1998) |
| | Divgi et al., "Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250," <u>European Journal of Nuclear Medicine</u> , 19(8): 578 (Abstract 121-3) (August 23, 1992) |
| | Divgi et al., "Radioimmunotherapy (RIT) with I-131 Monoclonal Antibody (Mab) G250 in Metastatic Renal Cancer," <u>Proceedings of the 41st Annual Meeting</u> , 35(5): 101P (Abstract #401) (May 1994) |
| | Divgi et al., "Radioimmunotherapy with I-131-G250 in Metastatic Renal Cell Cancer (RCC)," <u>J. Nucl. Med.</u> , 36 (5 Suppl.): 913P (Abstract 956; May 1995) |
| | Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," <u>PNAS (USA)</u> , 85: 8998-9002 (December 1988) |
| JB | Frosch et al., "Cloning and characterisation of an immunodominant major surface antigen of <u>Echinococcus multilocularis</u> ," <u>Molecular and Biochemical Parasitology</u> , 48: 121-130 (1991) |

EXAMINER

Daniel Blahut

DATE CONSIDERED

3/10/04

| | | |
|---|-----------------------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT | ATTY. DOCKET NO. D-0021.5-2 | SERIAL NO. 09/967,237 |
| | APPLICANT Zavada et al. | |
| | FILING DATE September 27, 2001 | GROUP |

**OTHER DISCLOSURES**

| | |
|-----------|---|
| <i>DB</i> | Liao et al., "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes," <u>PNAS (USA)</u> 95: 12596-12601 (October 1998) |
| | Karttunen et al., "Colorectal Tumors Show Abnormal Expression of MN/CA IX," <u>Pathology Research and Practice</u> 193/5-6: 392 Abstract No. P198 (Abstract from European Congress on Pathology at Maastricht; August 31 - September 4, 1997) |
| | Kranenborg et al., "Development and Characterization of Anti-Renal Cell Carcinoma X Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma," <u>Cancer Res.</u> , 55 (23 Suppl.) 5864s-5867s (1995) |
| | Kurth et al., "Characterization of Human Renal Cell Carcinoma Tumor Lines by Means of Monoclonal Antibodies," <u>Prostate</u> , 6(4): 451 (Abstract) (1985) |
| | Liao et al., "Identification of the MN Antigen as a Diagnostic Biomarker of Cervical Intraepithelial Squamous and Glandular Neoplasia and Cervical Carcinomas," <u>American Journal of Pathology</u> , 145(3): 598-609 (September 1994) |
| | Liao and Stanbridge, "Expression of the MN Antigen in Cervical Papanicolaou Smears Is an Early Diagnostic Biomarker of Cervical Dysplasia," <u>Cancer Epidemiology, Biomarkers & Prevention</u> , 5: 549-557 (July 1996) |
| | Liao et al., "Identification of the MN/CA9 Protein As a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the Kidney," <u>Cancer Research</u> , 57: 2827-2831 (July 15, 1997) |
| | Luiten et al., "Target-Specific Activation of Mast Cells by Immunoglobulin E Reactive with a Renal Cell Carcinoma-Associated Antigen," <u>Laboratory Investigation</u> , 74(2): 467-475 (1996) |
| <i>DB</i> | Luiten et al., "Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma," <u>British Journal of Cancer</u> , 74(5): 735-744 (1996) |

EXAMINER


Paul Blustein

DATE CONSIDERED

3/10/04

SERIAL NO.
09/967,237

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
D-0021.5APPLICANT
Zavada et al.FILING DATE
September 27, 2001

GROUP

OTHER DISCLOSURES

DB

Lunetta et al., "Monoclonal Antibodies to Kidney and Tumor-associated Surface Antigens of Human Renal Cell Carcinoma," Cancer Res., 46(11): 5816-5820 (1986)

McKiernan et al., "Expression of the Tumor-associated Gene MN: A Potential Biomarker for Human Renal Cell Carcinoma," Cancer Research, 57: 2362-2365 (June 15, 1997)

Moon et al., "A Highly Restricted Antigen for Renal Cell Carcinoma Defined by a Monoclonal Antibody," Hybridoma, 4(2): 163-172 (1985)

Nakagawa et al., "MN as a Potential Target in Renal Cell Carcinoma," J. Urology, 159 (5 Suppl.): 187, Abstract 720 (May 1998)

Oosterwijk and Debruyne, "Radiolabeled monoclonal antibody G250 in renal-cell carcinoma," World Journal of Urology, 13: 186-190 (1995)

Oosterwijk et al., "The Expression of Renal Antigens in Renal Cell Carcinoma," World Journal of Urology, 2(2): 156-158 (1984)

Oosterwijk et al., "Monoclonal Antibodies that Discriminate Between Renal Cell Carcinomas (RCC) and Other Malignancies," Prostate, 6(4): 451-452 (Abstract) (1985)

Oosterwijk et al., "Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens -- Application in the Diagnosis of Renal Cell Carcinoma," American Journal of Pathology, 123(2): 301-309 (May 1986)

DB

Oosterwijk et al., "Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney," Int. J. Cancer, 38: 489-494 (1986)

EXAMINER

*Harold Blasbal*DATE CONSIDERED *3/10/04*

ATTY. DOCKET NO.
D-0021.5B-2SERIAL NO.
09/967,237APPLICANT
Zavada et al.FILING DATE
September 27, 2001

GROUP

INFORMATION DISCLOSURE STATEMENT

RECEIVED
OCT 19 2001
PATENT & TRADEMARK OFFICE

OTHER DISCLOSURES

| | |
|----|---|
| DB | Oosterwijk et al., "Relationship between DNA Ploidy, Antigen Expression and Survival in Renal Cell Carcinoma," <u>Int. J. Cancer</u> , 42: 703-708 (1988) |
| | Oosterwijk et al., "Expression of Intermediate-sized Filaments in Developing and Adult Human Kidney and Renal Cell Carcinoma," <u>The Journal of Histochemistry and Cytochemistry</u> , 38(3): 385-392 (1990) |
| | Oosterwijk et al., "Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250," <u>Journal of Clinical Oncology</u> , 11(4): 738-750 (April 1993) |
| | Oosterwijk et al., "The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma," <u>Seminars in Oncology</u> , 22(1): 34-41 (February 1995) |
| | Oosterwijk et al., "Molecular characterization of the Renal Cell Carcinoma-associated antigen G250," <u>Proceedings of the American Association for Cancer Research</u> , 37: 461 (Abstract #3147) (March 1996) |
| | Oosterwijk et al., "Molecular Characterization of the Renal Cell Carcinoma-Associated Antigen G250," <u>J. Urol.</u> , 155: 925 (May 1996) |
| | Opavsky et al., "Regulation of MN Expression," <u>Cell Biology International</u> , 18(5): Abstract No. Mo-58 (1994) |
| | Opavsky et al., "Human MN/CA9 Gene a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships," <u>Genomics</u> , 33: 480-487 (1996) |
| DB | Pastorek et al., "The Structure and Expression of MN Gene, Coding for a Tumor-Associated Protein p54/58N," <u>J. Cancer Res., Clin. Oncol.</u> , 119 (Suppl. 1) 10/113 (1993) |

EXAMINER

Samuel Blustein

DATE CONSIDERED

3/10/04

ATTY. DOCKET NO.
D-0021.52SERIAL NO.
09/967, 237APPLICANT
Zavada et al.FILING DATE
September 27, 2001

GROUP

INFORMATION DISCLOSURE STATEMENT



OTHER DISCLOSURES

DB
Pastorek et al., "Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment," Oncogene, 9: 2877-2888 (1994)

Pastorek et al., "MN - A Novel Type of Oncoprotein," Cell Biology International, 18(5): Abstract No. Mo-57 (1994)

Pastorekova et al., "A Novel Quasi-viral Agent, MaTU, Is a Two-Component System," Virology, 187: 620-626 (1992)

Pastorekova et al., "Transformation of Mammalian Cells by MN Oncogene," Cell Biology International, 18(5): Abstract No. Mo-56 (1994)

Pastorekova et al., "MN/CA IX, a Carbonic Anhydrase Isoenzyme Implicated in Carcinogenesis," Abstract submitted to International Conference on Experimental and Clinical Oncology, Greece (October 3-5, 1996)

Pastorekova et al., "Carbonic Anhydrase IX, MN/CA IX: Analysis of Stomach Complementary DNA Sequence and Expression in Human and Rat Alimentary Tracts," Gastroenterology, 112: 398-408 (1997)

Resnick et al., "Viral and Histopathologic Correlates of MN and MIB-1 Expression in Cervical Intraepithelial Neoplasia," Human Pathology, 27(3): 234-239 (March 1996)

Reuters News Report, "Biomarker Resolves Ambiguous Pap Smears" (March 26, 1998)

DB
Saarnio et al., "Distribution of carbonic anhydrase isoenzymes I, II, IV, V, VI and MN/CA IX in the human intestine. An immunohistochemical study," Abstract submitted to the meeting for United European Gastroenterological Week, Paris (November 2-6, 1996)

EXAMINER

Janet Blanket


DATE CONSIDERED

3/10/04

ATTY. DOCKET NO.
D-0021.52SERIAL NO.
09/967,237APPLICANT
Zavada et al.FILING DATE
September 27, 2001

GROUP

INFORMATION DISCLOSURE STATEMENT



OTHER DISCLOSURES

DB
Saarnio et al., "Expression of a Novel Carbonic Anhydrase Isoenzyme, MN/CA IX, In Gallbladder and Hepatitic Tumours," Gut, 41(3) : PA186-A186 (1997)

Saarnio et al., "Immunohistochemistry of Carbonic Anhydrase Isozyme IX (MN/CA IX) in Human Gut Reveals Polarized Expression in the Epithelial Cells with the Highest Proliferative Capacity," Journal of Histochemistry & Cytochemistry 46(4) : 497-504 (1998)

Saarnio et al., "Immunohistochemical Study of Colorectal Tumors for Expression of a Novel Transmembrane Carbonic Anhydrase, MN/CA IX, with Potential Value as a Marker of Cell Proliferation," American Journal of Pathology, 153(1) : 279-285 (July 1998)

Stanbridge, E., "Cervical marker can help resolve ambiguous Pap smears," Diagnostics Intelligence, 10(5) : 11 (1998)

Steffens et al., "Radioimmunotargeting with I¹³¹ labeled chimeric G250 monoclonal antibody in patients with renal cell carcinoma," J. Nucl. Med., 37 (5 Suppl.) : 169P (1996)

Steffens et al., "Targeting of Renal Cell Carcinoma with Iodine-131-Labeled Chimeric Monoclonal Antibody G250," Journal of Clinical Oncology, 15(4) : 1529-1537 (April 1997)

Steffens et al., "Radioimmunotherapy with I¹³¹I-cG250 Monoclonal antibody in Patients with Metastasized RCC, Phase I/II Study," J. Urology, 159 (5 Suppl.) : Abstract 562 (May 1998)

Surfus et al., "Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors," Journal of Immunotherapy 19(3) : 184-191 (1996)

Surfus et al., "Renal Cell Human-Mouse Chimeric Antibody G250 Mediates Antibody Dependent Cellular Cytotoxicity (ADCC)," Biological Abstracts, 47(9) : 161224 (Abstract 3922) (1995)

EXAMINER

David Blehm

DATE CONSIDERED

3/10/04

ATTY. DCKET NO.
D-0021.52SERIAL NO.
09/967,237APPLICANT
Zavada et al.FILING DATE
September 27, 2001

GROUP

INFORMATION DISCLOSURE STATEMENT



OTHER DISCLOSURES

| | |
|----|--|
| JB | Turner et al., "MN Antigen Expression in Normal, Preneoplastic, and Neoplastic Esophagus: a Clinicopathological Study of a New Cancer-Associated Biomarker," <u>Hum. Pathol.</u> , 28(6): 740-744 (June 1997) |
| \ | Tweedie and Edwards, "Mouse Carbonic Anhydrase III: Nucleotide Sequence and Expression Studies," <u>Biochemical Genetics</u> , 27(1/2): 17-30 (1989) |
| \ | Uemura et al., "Internal Image Anti-Idiotype Antibodies Related to Renal-Cell Carcinoma-Associated Antigen G250," <u>Int. J. Cancer</u> , 56: 609-614 (1994) |
| \ | Uemura et al., "Vaccination with Anti-Idiotype Antibodies Mimicking a Renal Cell Carcinoma-Associated Antigen Induces Tumor Immunity," <u>Int. J. Cancer</u> , 58: 555-561 (1994) |
| \ | Uemura et al., "Immunization with Anti-Idiotype Monoclonal Antibodies Bearing the Internal Image of the Renal-Cell Carcinoma-Associated Antigen G250 Induces Specific Cellular Immune Responses," <u>Int. J. Cancer</u> , 59: 802-807 (1994) |
| \ | Uemura et al., "Anti-tumor effects of vaccination with internal image anti-idiotype monoclonal antibodies," <u>Biotherapy</u> (Japan), 9(3): 294-295 (1995) (English Language Summary) |
| \ | Uemura et al., "Possible tools for active specific immunotherapy with anit-idiotype antibodies in human renal cell carcinoma," <u>Biotherapy</u> (Japan), 10(3): 241-244 (1996) (English Lanugage Summary) |
| \ | Uemura et al., "Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target," <u>Journal Urology</u> , 157 (4-Supp.): 377 (April 16, 1997) |
| JB | Uemura et al., "MN Target Immunotherapy for Renal Cell Carcinoma," <u>J. Urology</u> , 159 (5 Suppl.): 187, Abstract No. 724 (1998) |

EXAMINER

*Paul Blaser*DATE CONSIDERED *3/10/04*

| | | | |
|---|--|-----------------------------------|--------------------------|
| INFORMATION DISCLOSURE STATEMENT | | ATTY. DOCKET NO. D-0021.52 | SERIAL NO. 09/967,237 |
| | | APPLICANT Zavada et al. | |
| | | FILING DATE September 27, 2001 | GROUP |

**OTHER DISCLOSURES**

| | |
|----|---|
| DB | Van Dijk et al., "Induction of Tumor-Cell Lysis by Bi-Specific Monoclonal Antibodies Recognizing Renal-Cell Carcinoma and CD3 Antigen," <u>Int. J. Cancer</u> , <u>43</u> : 344-349 (1989) |
| | Van Dijk et al., "Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, In Mice with Renal-Cell Carcinoma Xenografts," <u>Int. J. Cancer</u> , <u>56</u> : 262-268 (1994) |
| | Vermylen et al., "Expression of the MN antigen as a biomarker of lung carcinoma and associated precancerous conditions," <u>Proceedings of the American Association for Cancer Research</u> , (Abstract #2280) (March 1998) |
| | Vessella et al., "Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens," <u>Cancer Res.</u> , <u>45</u> (12, Pt. 1): 6131-6139 (1985) |
| | Young and Davis, "Efficient Isolation of Genes by Using Antibody Probes," <u>PNAS (USA)</u> <u>80</u> : 1194-1198 (March 1983) |
| | Zavada, "The Pseudotypic Paradox," <u>J. gen. Virol.</u> , <u>63</u> : 15-24 (1982) |
| | Zavada and Zavadova, "A Transmissible Antigen Detected in Two Cell Lines Derived from Human Tumours," <u>J. gen. Virol.</u> , <u>24</u> : 327-337 (1974) |
| | Zavada and Zavadova, "An unusual transmissible agent -- MaTu," <u>Arch. Virol.</u> , <u>118</u> : 189-197 (1991) |
| DB | Zavada et al., "VSV Pseudotype Produced in Cell Line derived from Human Mammary Carcinoma," <u>Nature New Biology</u> , <u>240</u> : 124-125 (November 22, 1972) |

EXAMINER

Pamela Bluhm

DATE CONSIDERED

3/10/04

ATTY. DOCKET NO.
D-0021.52SERIAL NO.
09/967,237APPLICANT
Zavada et al.FILING DATE
September 27, 2001

GROUP

INFORMATION DISCLOSURE STATEMENT**OTHER DISCLOSURES**

| | |
|----|---|
| DB | Zavada et al., "Tumorigenicity-Related Expression of MaTu Proteins in HeLa x Fibroblast Hybrids," Abstract presented at the XIX Meeting of the European Tumor Virus Group (May 1-4, 1991) |
| | Zavada et al., "A Presumed New Oncoprotein - MN - Used as Experimental Antitumor Vaccine," <u>J. Cancer Res. Clin. Oncol.</u> , 119, (Suppl. 1) 2/24 (1993) |
| | Zavada et al., "Expression of MaTu-MN Protein in Human Tumor Cultures and in Clinical Specimens," <u>Int. J. Cancer</u> , 54: 268-274 (1993) |
| | Zavada et al., "MN - A Novel Type of Human Oncogene," Abstract submitted to EMBL Conference: Oncogenes & Growth Control, Heidelberg (21-24 April 1996) |
| | Zavada et al., "A novel oncoprotein, MN, implicated in cervical carcinoma," Abstract submitted to ETVG Meeting, Innsbruck (March 1997) |
| | Zavada et al., "Transient transformation of mammalian cells by MN protein, a tumor-associated cell adhesion molecule with carbonic anhydrase activity," <u>International Journal of Oncology</u> , 10: 857-863 (1997) |
| DB | Zavadova et al., "Novel tumor-associated MN protein is a cell adhesion molecule," for conference on Molecular Genetics of Cancer, Oxford, September 1997 |
| | |
| | |

EXAMINER

Paul Blitner

DATE CONSIDERED

3/10/04